Pembrolizumab Biosimilar Antibody

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. Pembrolizumab is a therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The PD-1 receptor is generally responsible for preventing the immune system from attacking the body’s own tissues, via a so-called immune checkpoint mechanism.

Pembrolizumab is an IgG4 isotype antibody, with a variable region against the human PD-1 receptor, a humanized mouse monoclonal [228-L-proline(H10-S>P)]γ4 heavy chain (134-218) disulfide and a humanized mouse monoclonal κ light chain dimer (226-226:229-229)-bisdisulfide.